Nicholas A. J. Dawson

Nicholas A. J. Dawson

Auto-generated profile, based on publicly available information

Nicholas A. J. Dawson

Department of Medicine, University of British Columbia, Vancouver, BC V5Z 4H4, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
KMKatherine G. MacDonald
Katherine G. MacDonald
NDNicholas A.J. Dawson
Nicholas A.J. Dawson
QHQing Huang
Qing Huang
JDJames V. Dunne
James V. Dunne
MLMegan K. Levings
Megan K. Levings
RBRaewyn Broady
Raewyn Broady

19 August 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
NDNicholas A. J. Dawson
Nicholas A. J. Dawson
IRIsaac Rosado-Sánchez
Isaac Rosado-Sánchez
GNGerman E. Novakovsky
German E. Novakovsky
VFVivian C. W. Fung
Vivian C. W. Fung
QHQing Huang
Qing Huang
MLMegan K. Levings
Megan K. Levings
Comparison of 10 co-receptor variant CARs revealed a requirement for CD28wt for optimal suppression by human regulatory T cells.

21 March 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
NDNicholas A.J. Dawson
Nicholas A.J. Dawson
CLCaroline Lamarche
Caroline Lamarche
RHRomy E. Hoeppli
Romy E. Hoeppli
PBPeter Bergqvist
Peter Bergqvist
VFVivian C.W. Fung
Vivian C.W. Fung
MLMegan K. Levings
Megan K. Levings
Chimeric antigen receptor (CAR) technology can be used to engineer the antigen specificity of regulatory T cells (Tregs) and improve their potency as an adoptive cell therapy in multiple disease models. As synthetic receptors, CARs carry the risk of immunogenicity, particularly when derived from nonhuman antibodies. Using an HLA-A*02:01–specific CAR (A2-CAR) encoding a single-chain variable fragment (Fv) derived from a mouse antibody, we developed a panel of 20 humanized A2-CARs (hA2-CARs). Systematic testing demonstrated variations in expression, and ability to bind HLA-A*02:01 and stimulate human Treg suppression in vitro. In addition, we developed a new method to comprehensively map the alloantigen specificity of CARs, revealing that humanization reduced HLA-A cross-reactivity. In vivo bioluminescence imaging showed rapid trafficking and persistence of hA2-CAR Tregs in A2-expressing allografts, with eventual migration to draining lymph nodes. Adoptive transfer of hA2-CAR Tregs suppressed HLA-A2 + cell–mediated xenogeneic graft-versus-host disease and diminished rejection of human HLA-A2 + skin allografts. These data provide a platform for systematic development and specificity testing of humanized alloantigen-specific CARs that can be used to engineer specificity and homing of therapeutic Tregs.

3 November 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
NDNicholas A. J. Dawson
Nicholas A. J. Dawson
JVJens Vent-Schmidt
Jens Vent-Schmidt
MLMegan K. Levings
Megan K. Levings
Regulatory T cells (Tregs) are potent suppressors of immune responses and are currently being clinically tested for their potential to stop or control undesired immune responses in autoimmunity, hematopoietic stem cell transplantation and solid organ transplantation. Current clinical approaches aim to boost Tregs in vivo either by using Treg-promoting small molecules/proteins and/or by adoptive transfer of expanded Tregs. However, the applicability of Treg-based immunotherapies continues to be hindered by technical limitations related to cell isolation and expansion of a pure, well-characterized and targeted Treg product. Efforts to overcome these limitations and improve Treg-directed therapies are now under intense investigation in animal models and pre-clinical studies. Here we review cell and protein engineering-based approaches that aim to target different aspects of Treg biology including modulation of IL-2 signaling or FOXP3 expression, and targeted antigen-specificity using transgenic T cell receptors or chimeric antigen receptors. With the world-wide interest in engineered T cell therapy, these exciting new approaches have the potential to be rapidly implemented and developed into therapies that can effectively fine-tune immune tolerance.

1 September 2017 in Translational Research
Verified
Journal Article
Closed access
NDNicholas A.J. Dawson
Nicholas A.J. Dawson
MLMegan K. Levings
Megan K. Levings

1 March 2016 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DWD. Wu
D. Wu
NDN. A. J. Dawson
N. A. J. Dawson
MLM. K. Levings
M. K. Levings
Obesity is often associated with the development of adipose tissue (AT) inflammation, resulting in metabolic dysfunction and an increased risk for developing type 2 diabetes. It is also associated with multiple chronic diseases, including cardiovascular, liver, and kidney disease, and thus can contribute to organ failure. Several studies have investigated whether there is a correlation between obesity and outcomes in transplantation, but there is currently very limited information on the specific role of AT inflammation in the rejection process or on the overall function of the transplanted organ. Here, we provide a brief review of the current understanding of the cellular mechanisms that control obesity-associated AT inflammation and summarize knowledge about how obesity affects clinical outcomes following solid organ or hematopoietic stem cell transplantation. We also highlight opportunities for more research to better understand how obesity affects outcomes of transplantation.